0EVI.LSE Innate Pharma S.A.

Healthcare Commercial Services & Supplies London Exchange
3.37 EUR
Close of Oct 3, 2026
1.04 2.33
Market cap
EUR 194M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.

Is 0EVI.LSE undervalued?

Graham number

The Graham number of Innate Pharma S.A. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Innate Pharma S.A. fundamental analysis

No fundamental analysis for Innate Pharma S.A. yet.

Innate Pharma S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Innate Pharma S.A.

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that…

Full company profile